Loading
Hemoglobinopathies and Related Disorders / Iron Metabolism and Disorders · Journal article
Current Obesity Reports · September 5, 2026
A consensus or society position rather than new primary data.
This narrative review describes how obesity disturbs iron metabolism through hepcidin-mediated mechanisms, producing a heterogeneous iron phenotype that is often misclassified using single biomarkers. The authors recommend multi-marker assessment (ferritin with inflammation markers, transferrin saturation, soluble transferrin receptor) and management addressing reversible inflammation via weight loss, guided by likelihood of true iron deficiency versus hepcidin-mediated oral refractoriness, avoiding reflexive phlebotomy for dysmetabolic hyperferritinemia without confirmed overload.
Journal article. Adults and children with obesity; emphasis on women with obesity..
In obesity, interleukin-6 drives hepatic hepcidin through JAK/STAT3 signaling, while leptin, adipose hypoxia, and adipose hepcidin expression may contribute additional signals. Women with obesity may have higher hepcidin, ferritin, and inflammatory markers but lower serum iron, producing hypoferremia and iron-restricted erythropoiesis despite normal or elevated ferritin. Stable-isotope and intervention studies suggest weight loss reduces inflammation and hepcidin and improves iron absorption.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should not rely on ferritin alone to assess iron status in obese patients, as inflammation-driven hepcidin elevation can produce high ferritin with concurrent iron deficiency. A multi-marker approach incorporating C-reactive protein or other inflammation markers, along with transferrin saturation or soluble transferrin receptor, is needed to correctly classify iron status and guide treatment decisions, particularly before phlebotomy or iron supplementation.
A narrative review synthesizing mechanistic evidence and clinical frameworks for interpreting iron status in obesity, providing expert recommendations for assessment and management rather than reporting a novel empirical finding.
Clinicians should not rely on ferritin alone to assess iron status in obese patients, as inflammation-driven hepcidin elevation can produce high ferritin with concurrent iron deficiency. A multi-marker approach incorporating C-reactive protein or other inflammation markers, along with transferrin saturation or soluble transferrin receptor, is needed to correctly classify iron status and guide treatment decisions, particularly before phlebotomy or iron supplementation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Purpose of Review Obesity reshapes systemic iron handling, yet the resulting iron phenotype is frequently misclassified at the bedside and in population studies. This review examines how excess adiposity disturbs iron metabolism and complicates iron-status assessment, with balanced attention to biology and measurement problems across adults and children. Recent Findings Adipose tissue is an endocrine, inflammatory, and iron-handling organ. In obesity, interleukin-6 drives hepatic hepcidin through JAK/STAT3 signaling, while leptin, adipose hypoxia, and adipose hepcidin expression may contribute additional signals. Hepcidin degrades ferroportin, reducing duodenal iron export and limiting macrophage iron release, producing hypoferremia and iron-restricted erythropoiesis despite normal or elevated ferritin. We and others have shown that women with obesity may have higher hepcidin, ferritin, and inflammatory markers but lower serum iron. Stable-isotope and intervention studies suggest weight loss reduces inflammation and hepcidin and improves iron absorption, whereas the World Health Organization and Biomarkers of Nutrition for Development frameworks recommend interpreting ferritin relative to inflammation. Summary Iron status in obesity spans a continuum from absolute or functional iron deficiency to sufficiency and, in some individuals, hyperferritinemia with possible dysmetabolic iron overload. Reliable assessment requires a multi-marker strategy: ferritin interpreted alongside an inflammation marker such as C-reactive protein and supported by transferrin saturation, soluble transferrin receptor, reticulocyte hemoglobin, or other context-appropriate indices. Management should address reversible inflammation through weight loss and metabolic risk reduction, use oral or intravenous iron according to the likelihood of true deficiency and hepcidin-mediated oral refractoriness, and avoid reflexive phlebotomy for dysmetabolic hyperferritinemia without confirmed overload.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.